Vir Biotechnology ex-director plans $165K share sale

The shares are listed as acquired from the issuer through a cash-paid stock option exercise dated June 29, 2026.

Accepted by SEC EDGAR 06/29/2026 - 03:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) is the issuer named in a notice listing 16,000 common shares for sale for Saira Ramasastry, a former director, with an approximate sale date of June 29, 2026. The listed aggregate market value is $165,138.95. The shares are listed as acquired from the issuer through a stock option exercise on June 29, 2026, with cash payment; Fidelity Brokerage Services LLC is named as broker.

Key Figures

Shares listed for sale: 16,000 common shares Aggregate market value: $165,138.95 Common shares outstanding: 168,651,974 shares

3 metrics

Shares listed for sale 16,000 common shares Approximate sale date: June 29, 2026

Aggregate market value $165,138.95 Common shares listed for sale

Common shares outstanding 168,651,974 shares Securities information

Key Terms

Aggregate Market Value, Stock Option Exercise, attorney-in-fact

3 terms

Aggregate Market Value financial

"Aggregate Market Value | 165138.95"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Stock Option Exercise financial

"Nature of Acquisition Transaction | Stock Option Exercise"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as attorney-in-fact for Saira Ramasastry"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VIR shares is Saira Ramasastry planning to sell?

Saira Ramasastry, a former director, is listed as selling 16,000 common shares, with an approximate sale date of June 29, 2026. The listed aggregate market value is $165,138.95.

How did Saira Ramasastry acquire the VIR shares listed for sale?

The shares are listed as acquired from the issuer through a stock option exercise on June 29, 2026, with cash payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001547959
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	Ramasastry Saira
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	16000	165138.95	168651974	06/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/29/2026	Stock Option Exercise	Issuer			16000	06/29/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	06/29/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Saira Ramasastry
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)